Orvacabtagene Autoleucel (JCARH125)


JCARH125 is a CAR T-cell product that targets B-cell maturation antigen (BCMA).

On February 11, 2021, it was announced that Bristol Myers Squibb was abandoning further development on Orvacabtagene Autoleucel - a BCMA CAR T cell therapy originally developed by Juno Therapeutics.

SparkCures ID 308
Developed By Juno Therapeutics, a Subsidiary of Celgene
Generic Name Orvacabtagene Autoleucel (JCARH125)
Treatment Classifications
Treatment Targets

Clinical Trials

Published Results

ASCO 2020 Interim Results (EVOLVE)

May 29, 2020

  • Orva-cel's phase I/II Evolve trial now has 62 evaluable subjects, 22 of whom are said to have had a complete remission, with a further 35 in partial remission.
  • Overall Response Rate (ORR) 92%.